Flu

The BMJ study highlights that young children vaccinated against influenza in October experience the greatest protection, with lower infection rates than those vaccinated earlier.

Research reveals how aging impacts flu severity in older adults, highlighting the need for enhanced vaccines and new therapeutic strategies.

New findings suggest high-dose influenza vaccines offer better protection against the flu and reduce cardiac complications in older adults.

FluMist Home, the first at-home nasal spray flu vaccine, is now available for direct delivery to patients in 34 US states.

Researchers unveil a promising drug combination, arainosine and theobromine, that effectively targets influenza A M2 channels, outperforming existing treatments.

New research confirms oseltamivir (Tamiflu; Roche) is safe for children, reducing flu-related neuropsychiatric risks and encouraging timely antiviral treatment.

Collaborating with local organizations strengthens trust and can influence vaccination uptake.

Understanding the regulatory landscape can maximize pharmacists' roles while ensuring legal compliance.

Many factors contribute to vaccine skepticism, including trust, convenience, and fear.

CDC's ACIP recommends removing thimerosal from flu vaccines, igniting debate on vaccine safety and fueling antivaccine sentiments amid public health concerns.

Administering influenza, COVID-19, and RSV immunizations at the same time may improve vaccine uptake.

Lessons from the past season could strengthen prevention and drive vaccinations for 2025-2026.

Influenza vaccination significantly reduces cases and enhances community immunity, highlighting pharmacists' vital role in promoting public health.

Influenza Vaccination Preparation Should Be on the Docket for Any Pharmacy After a Much-Anticipated ACIP Meeting

New research highlights the benefits of early oseltamivir treatment for hospitalized patients with influenza, reducing mortality and readmission rates while optimizing care.

New research reveals that extracellular vesicles enhance intranasal flu vaccines, boosting mucosal immunity and offering broader protection against diverse strains.

Moderna's mRNA-1010 flu vaccine shows promising efficacy, especially for older adults, addressing the urgent need for better influenza prevention.

With the Advisory Committee on Immunization Practices recommending that adults receive thimerosal-free influenza vaccines, the preservative that was phased out of most childhood vaccines in 2001 has reentered the public eye.

The Advisory Committee on Immunization Practices (ACIP) voted 5-1, with 1 voter abstaining, to recommend that adults receive seasonal influenza vaccines that do not contain the preservative thimerosal.

The announcement is set to affect multiple grants awarded to Moderna, which is developing mRNA-1018, a candidate vaccine against avian influenza.

A new multicomponent vaccine, mRNA-1083, shows promise in enhancing immune responses against influenza and COVID-19, addressing vaccine hesitancy effectively.

Reductions of approximately 32% were observed during the study.

The only major change is in the included strain of influenza A/H2N2 virus, which has been updated for both the egg-based and the cell- and recombinant-based vaccines.

A district leader at CVS Health emphasizes that patients should get tested, be up to date with immunizations, and staying home and reach out to health care professionals when experiencing symptoms.

The decisions were made amid the United States worst flu outbreak in over 2 decades.